Aggressive Treatment of Intermediate-Risk Patients with Acute Symptomatic Pulmonary Embolism.
Clin Chest Med. 2018 Sep;39(3):569-581
Authors: Jimenez D, Bikdeli B, Marshall PS, Tapson V
Contemporary studies of acute pulmonary embolism (PE) have evaluated the role of thrombolytics in intermediate-risk PE. Significant findings are that thrombolytic therapy may prevent hemodynamic deterioration and all-cause mortality but increases major bleeding. Benefits and harms are finely balanced with no convincing net benefit from thrombolytic therapy among unselected patients. Among patients with intermediate risk PE, additional prognostic factors or subtle hemodynamic changes might alter the risk-benefit assessment in favor of thrombolytic therapy before obvious hemodynamic instability.
PMID: 30122181 [PubMed - in process]